Virus News and Research

Latest Virus News and Research

Biomagnetics Diagnostics obtains handheld IOBS unit to detect pathogens

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has received its first handheld integrated optical biosensor unit from Los Alamos National Security, LLC.

21 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

NanoBio to develop intranasal vaccine for HBV

NanoBio® Corporation today announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients.

20 Apr 2010

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

Though the world has made "great strides" in eliminating H5N1 (avian flu) from poultry since the "peak of its outbreak in 2006" in 63 countries, the virus persists in Bangladesh, China, Egypt, Indonesia and Vietnam, VOA News reports (DeCapua, 4/16).

20 Apr 2010

New research shows link between infection-related diseases and risk of cancer

New research is emerging that suggests a link between infection-related diseases and risk of cancer, according to findings presented here at the American Association for Cancer Research 101st Annual Meeting 2010.

20 Apr 2010

Study identifies protective relationship between gene variant and cognitive function in older people

New research shows a gene variant may help protect the memory and thinking skills of older people. The research will be published in the April 20, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

20 Apr 2010

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

NanoImaging Services, Inc., announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Center for Research Resources to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy. The grant provides approximately $200,000 in research and development funds for a Phase I study.

19 Apr 2010

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Myriad Pharmaceuticals, Inc. today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin Pharmaceuticals.

19 Apr 2010

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.

19 Apr 2010

RSCRC scientists explore mysteries of human embryonic stem cells

At Rutgers' Stem Cell Research Center scientists are exploring the mysteries of human embryonic stem cells and their potential use in treating diseases, repairing damaged organs, and drug development. Center staff also offer a course in proper lab techniques in working with stem cells.

17 Apr 2010

NVIC participates in NVAC-sponsored meeting to discuss the U.S. vaccine safety system

The National Vaccine Information Center participated in a meeting sponsored by the federal National Vaccine Advisory Committee and facilitated by The Keystone Center April 11-13 in Salt Lake City to discuss strengthening the U.S. vaccine safety system.

17 Apr 2010

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

24 weeks of treatment could be sufficient to cure between 93 and 100% of treatment-na-ve chronic hepatitis C virus (HCV) genotype 1 (G1) infected patients if they have a fast antiviral response to Telaprevir (TVR) with Peginterferon (PEG-IFN) and Ribavirin (RBV), according to new research presented today at the International Liver Congress 2010, the Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria.

17 Apr 2010

Immune system cells that impede wound-healing process discovered

A new discovery about the wound-healing process could lead to better treatments for diabetics and other patients who have wounds that are slow to heal.

17 Apr 2010

GeoVax Labs Labs announces 1-for-50 reverse stock split

GeoVax Labs, Inc., a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, today announced it will implement a 1-for-50 reverse stock split effective following the close of business on April 27, 2010. After the reverse stock split, the Company will be authorized to issue up to 40 million shares of stock, of which approximately 15.7 million shares will be outstanding.

17 Apr 2010

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

New data presented today at the International Liver CongressTM 2010 found a link between chronic hepatitis B virus and progression to cancers other than hepatocellular carcinoma.

16 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Investment report on Idenix Pharmaceuticals

StockPreacher.com announces an investment report featuring Idenix Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Apr 2010

Investment report on Anadys Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Anadys Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Apr 2010

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics.

16 Apr 2010

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

InterMune, Inc. today announced results of all three cohorts from a 15-day Phase 1b multiple-ascending-dose (MAD) study of low doses of danoprevir (also known as RG7227 and ITMN-191) boosted by low-dose ritonavir (RTV) in patients chronically infected with hepatitis C virus (HCV) genotype-1.

16 Apr 2010

Virus News and Research

Latest Virus News and Research

Biomagnetics Diagnostics obtains handheld IOBS unit to detect pathogens

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

NanoBio to develop intranasal vaccine for HBV

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

New research shows link between infection-related diseases and risk of cancer

Study identifies protective relationship between gene variant and cognitive function in older people

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Phase II study: Hepatitis C patients receiving ANA598 bid plus SOC attain undetectable levels of virus

RSCRC scientists explore mysteries of human embryonic stem cells

NVIC participates in NVAC-sponsored meeting to discuss the U.S. vaccine safety system

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

Immune system cells that impede wound-healing process discovered

GeoVax Labs Labs announces 1-for-50 reverse stock split

Study: Higher risk of NHL and Cholangiocarcinoma associated with HBV infection

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Investment report on Idenix Pharmaceuticals

Investment report on Anadys Pharmaceuticals

Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

InterMune reports Phase 1b MAD study results of RTV-boosted danoprevir in HCV patients at 45th EASL

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in